
BRVE Stock Forecast & Price Target
BRVE Analyst Ratings
Bulls say
Braveheart Bio is viewed positively because BHB-1893 targets a clinically validated cardiac myosin inhibition mechanism with differentiated PK/PD, including faster steady state, lower accumulation, fewer DDI liabilities, and a potentially wider therapeutic window that could simplify dosing. In oHCM, that could translate into comparable efficacy with fewer titration steps, echoes, and monitoring burdens, while in nHCM the phase 2 data were especially encouraging with about a 5.5-6 point placebo-adjusted KCCQ benefit, ~0.5 mL/kg/min pVO₂ improvement, and early remodeling signals. With the IPO raising about $440M and funding both global phase 3 programs through completion into ~2029, the company has a de-risked runway to key readouts in 4Q26, 1H27, 2H27, and beyond.
Bears say
Braveheart Bio is a clinical-stage company with no product revenue and likely needs additional capital, creating clear financing risk before BHB-1893 can ever generate value. Its lead asset has only shown encouraging KCCQ and remodeling signals in a relatively small 12-week phase 2 study, while the global NOBLEHEART-HCM phase 3 trial still must prove those results at scale and across a broader population. The bearish view is further reinforced by competition and regulatory uncertainty: approved myosin inhibitors already have REMS programs, EDG-7500 could alter the convenience landscape, and comparable efficacy in nHCM would weaken Braveheart’s differentiation, especially given geographic translation risk from Chinese data.
This aggregate rating is based on analysts' research of Braveheart Bio Inc. and is not a guaranteed prediction by Public.com or investment advice.
BRVE Analyst Forecast & Price Prediction
Start investing in BRVE
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Braveheart Bio Inc. (BRVE) Forecast
BRVE Analyst Forecast & Price Prediction
Start investing in BRVE
Order type
Buy in
Order amount
Est. shares
0 shares